WallStSmart

Redhill Biopharma Ltd (RDHL)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 149637% more annual revenue ($14.30B vs $9.55M). VTRS leads profitability with a -24.6% profit margin vs -97.5%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

RDHL

Avoid

31

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RDHL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
58.6%10/10

Revenue surging 58.6% year-over-year

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

RDHL4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.49M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.1%2/10

ROE of -17.1% — below average capital efficiency

Free Cash FlowQuality
$-2.51M2/10

Negative free cash flow — burning cash

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : RDHL

The strongest argument for RDHL centers on Revenue Growth. Revenue growth of 58.6% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : RDHL

The primary concerns for RDHL are EPS Growth, Market Cap, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

RDHL profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.

RDHL carries more volatility with a beta of 4.99 — expect wider price swings.

RDHL is growing revenue faster at 58.6% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Redhill Biopharma Ltd

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company is headquartered in Tel Aviv, Israel.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?